TNF and COVID-19: Study indicated that recipients of hUC‐MSCs had higher levels of soluble TNFR2 suggesting that binding of soluble TNFR2 to tumor necrosis factor (TNF) would inhibit TNF cytotoxicity and reduce inflammation in COVID‐19.16